# Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of of HZBio1 in Healthy Subjects

> **NCT04765995** · PHASE1 · COMPLETED · sponsor: **Hangzhou Grand Biologic Pharmaceutical, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** HZBio1 0.96mg / kg
- **DRUG:** HZBio1 3mg / kg
- **DRUG:** HZBio1 6mg / kg
- **DRUG:** HZBio1 9mg / kg
- **DRUG:** HZBio1 12mg / kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04765995
- **Lead sponsor:** Hangzhou Grand Biologic Pharmaceutical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2021-10-31
- **Final completion:** 2022-01-14
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04765995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04765995, "Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of of HZBio1 in Healthy Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04765995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*